Article Link: Epizyme Announces U.S. FDA Accelerated Approval of Tazverik (tazemetostat) for Relapsed/Refractory Follicular Lymphoma CAMB...
BioSig (NASDAQ: BSGM) Shares Setting up for Another Run? Multiple Near-Term Catalysts
BioSig (BSGM) is targeting the $4.6 billion electrophysiology (EP) market with their bioelectronic technology. The electrophysiology sector is growing...
FDA Approves Second Biomarker-Based Indication for Merck’s Keytruda (pembrolizumab), Regardless of Tumor Type
Article Link: FDA Approves Second Biomarker-Based Indication for Merck’s Keytruda (pembrolizumab), Regardless of Tumor Type KENILWORTH, N...
Cosentyx Receives FDA Approval for New Indication to Treat Active Non-Radiographic Axial Spondyloarthritis
Article Link: Cosentyx Receives FDA Approval for New Indication to Treat Active Non-Radiographic Axial Spondyloarthritis EAST HANOVER, N....
FDA Approves Zepzelca (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Article Link: FDA Approves Zepzelca (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer Madrid and Dublin, June 15th, ...
FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes
Article Link: FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes INDIANAPOLIS, June 15, 2020 /PRNewswire...
FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
Article Link: FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers KENILWORTH, N.J.–(BUS...
Did Last Weeks Market Dip Create Opportunity? A New Report Will be Available This Week
Good day everyone, The markets took a breather last week but finished strong with both the NASDAQ and the DJIA in the green. The DJIA gave up 6% for t...
FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Article Link: FDA Approves Uplizna (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) GAITHERSBURG, ...
FDA Approves Tivicay PD (dolutegravir) Once-Daily Dispersible Tablet Formulation for Children with HIV
Article Link: FDA Approves Tivicay PD (dolutegravir) Once-Daily Dispersible Tablet Formulation for Children with HIV London, UK – 1...